Lung Cancer: Frontline nivolumab — CheckMate 026 ends in stalemate
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2017.102
Abstract: is an approved second-line therapy for advanced-stage non-small-cell lung cancer (NSCLC), but earlier use of this immunotherapeutic agent might be beneficial. In the phase III CheckMate 026 trial, David Carbone et al. addressed this question.… read more here.
Keywords: mutation burden; checkmate 026; frontline nivolumab; lung cancer ... See more keywords